EP Patent

EP3812372A3 — 7-heterocyclyl substituted sancycline derivatives for treating bacterial, viral and parasitic infections (e.g. malaria) or inflammatory diseases

Assigned to Paratek Pharmaceuticals Inc · Expires 2021-06-30 · 5y expired

What this patent protects

The present invention relates to tetracycline derivatives, and in particular to sancycline derivatives substituted at their 7-position by a five-membered heterocyclic ring, for use in the treatment of bacterial, viral and/or parasitic infections, such as e.g. malaria, and/or infl…

USPTO Abstract

The present invention relates to tetracycline derivatives, and in particular to sancycline derivatives substituted at their 7-position by a five-membered heterocyclic ring, for use in the treatment of bacterial, viral and/or parasitic infections, such as e.g. malaria, and/or inflammatory diseases.

Drugs covered by this patent

Patent Metadata

Patent number
EP3812372A3
Jurisdiction
EP
Classification
Expires
2021-06-30
Drug substance claim
No
Drug product claim
No
Assignee
Paratek Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.